Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

Myeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months of diagnosis. We aimed to assess whether patients newly diagnosed with myeloma benefi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2019-12, Vol.20 (12), p.1760-1772
Hauptverfasser:	Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen, Dawkins, Bryony, Meads, David, Hulme, Claire T, Monahan, Irene, Karunanithi, Kamaraj, Dignum, Helen, Belsham, Edward, Neilson, Jeff, Harrison, Beth, Lokare, Anand, Campbell, Gavin, Hamblin, Michael, Hawkey, Peter, Whittaker, Anna C, Low, Eric, Dunn, Janet A
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anti-Bacterial Agents - therapeutic use Antibiotic Prophylaxis - methods Antibiotics Autografts Bacterial infections Cancer therapies Chemotherapy Clinical trials Double-Blind Method Double-blind studies Drug resistance Febrile Neutropenia - prevention & control Female Follow-Up Studies Glomerular filtration rate Humans Immunodeficiency Infections - drug therapy Levofloxacin Levofloxacin - therapeutic use Male Middle Aged Mortality Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Myeloma Neutropenia Ordination Pain Patients Prognosis Prophylaxis Prospective Studies Staphylococcus infections Stem cell transplantation Tablets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!